Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $959,200.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $17.44, for a total transaction of $959,200.00. Following the completion of the sale, the chief executive officer now directly owns 520,661 shares in the company, valued at approximately $9,080,327.84. The trade was a 9.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Saurabh Saha also recently made the following trade(s):

• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.46, for a total value of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.23, for a total transaction of $5,450.77.
• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.89, for a total value of $928,950.00.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.24, for a total value of $30,479.04.
• On Wednesday, October 23rd, Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.32, for a total value of $39,709.44.
• On Monday, October 21st, Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.80, for a total value of $350,839.00.

Centessa Pharmaceuticals Stock Down 2.2 %

CNTA stock opened at $17.16 on Friday. The business has a 50-day simple moving average of $16.64 and a 200 day simple moving average of $13.57. The company has a market cap of $2.26 billion, a PE ratio of -11.22 and a beta of 1.52. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 52 week low of $6.65 and a 52 week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Sell-side analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Analysts Set New Price Targets

CNTA has been the topic of several research reports. Jefferies Financial Group boosted their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. B. Riley began coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target for the company. Guggenheim upped their price objective on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Finally, BMO Capital Markets upped their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals has an average rating of “Buy” and an average target price of $25.83.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. First Light Asset Management LLC raised its position in Centessa Pharmaceuticals by 59.2% in the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after purchasing an additional 1,778,515 shares during the last quarter. Perceptive Advisors LLC raised its holdings in Centessa Pharmaceuticals by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock valued at $35,518,000 after buying an additional 850,000 shares during the last quarter. FMR LLC boosted its position in Centessa Pharmaceuticals by 4.6% during the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company’s stock worth $46,635,000 after buying an additional 129,300 shares during the period. Point72 Asset Management L.P. grew its holdings in Centessa Pharmaceuticals by 54.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock worth $43,423,000 after acquiring an additional 953,659 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after acquiring an additional 1,145,823 shares during the period. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.